Hints and tips:
...Many of the latter saw a chance to form relationships with the bioscience companies at an early stage in their development....
...This month many US investors have been repositioning their portfolios to account for the growing feeling there will be no V-shaped recovery....
...Schering has made efforts to reduce its dependence on cholesterol drugs, particularly with its $14bn acquisition of Organon BioSciences....
...The fallout for Mr Lee from that story was predictable: three months later, Chase coughed up about $500m for the Beacon Group, a tiny mergers and acquisitions boutique, to obtain the services and cachet...
International Edition